Cifarma Científica Farmacêutica LTDA.

cifarma.com.br

Cifarma is a genuinely Brazilian company that was born in Santa Luzia (MG). Founded in 1999 in the era of globalization and with the need to combine technology with humanistic values. In 2002 the company inaugurated its new industrial park installed in an area of ​​100,000 m², in Goiânia (GO), a strategic region for the distribution of its products throughout the country.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

FARMACON GLOBAL PARTNERS WITH VALIDCARE FOR PERFORMANCE-BASED CLINICAL RESEARCH SOLUTIONS

Validcare | February 17, 2022

news image

“Validcare’s partnership with Farmacon Global will literally redefine clinical trial success from patient-centric design through database lock,” said Patrick McCarthy CEO Validcare. The Validcare platform accommodates site-based, hybrid and decentralized clinical trials and establishes key performance indicators to ensure study success. “Partnering with Validcare allows our sponsors to quickly identify and implement ROI generating acti...

Read More

Business Insights

ORAMED COMPLETES PATIENT ENROLLMENT IN PHASE 2 ORAL INSULIN NASH TRIAL

Oramed Pharmaceuticals Inc. | March 17, 2022

news image

Oramed Pharmaceuticals Inc. a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced it has completed enrollment of all patients in a Phase 2 trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis. An estimated 1.5% to 6.5% of adults in the U.S., or between 4 million and 17 million people, have NASH and about half of these also have diabetes, according to the National Institute of Diabetes and Dige...

Read More

Business Insights

OPTIMIZERX ACQUIRES EVINCEMED, A SPECIALTY DRUG PRESCRIPTION INITIATION PLATFORM

OptimizeRx Corporation | March 16, 2022

news image

OptimizeRx Corp. a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced a definitive agreement to acquire the EvinceMed platform and related assets. EvinceMed is a leader in delivering end-to-end automation for specialty pharmaceutical transactions. The acquisition includes the full Market Access Management Platform supporting pharma manufacturers, hub providers and pharmacies to improve patient access, speed to therapy and activation of af...

Read More

PHARMACY MARKET, PHARMA TECH

TETRA BIO-PHARMA ANNOUNCES RESULTS OF ARTIFICIAL INTELLIGENCE STUDY OF ARDS-003 COMBINED WITH FAVIPIRAVIR

Tetra Bio-Pharma Inc. | December 07, 2022

news image

Tetra Bio-Pharma Inc. a leader in cannabinoid-derived drug discovery and development announced significant results from the study of Onternabez combined with Favipiravir against ARDS powered platform which purposely integrates target identification, validation, lead discovery optimization, drug synthesis, and preclinical testing. Leveraging the power of AI enables more answers and greater insights, faster. Results from the study demonstrate that Tetra's investigational therape...

Read More
news image

Pharmacy Market

FARMACON GLOBAL PARTNERS WITH VALIDCARE FOR PERFORMANCE-BASED CLINICAL RESEARCH SOLUTIONS

Validcare | February 17, 2022

“Validcare’s partnership with Farmacon Global will literally redefine clinical trial success from patient-centric design through database lock,” said Patrick McCarthy CEO Validcare. The Validcare platform accommodates site-based, hybrid and decentralized clinical trials and establishes key performance indicators to ensure study success. “Partnering with Validcare allows our sponsors to quickly identify and implement ROI generating acti...

Read More
news image

Business Insights

ORAMED COMPLETES PATIENT ENROLLMENT IN PHASE 2 ORAL INSULIN NASH TRIAL

Oramed Pharmaceuticals Inc. | March 17, 2022

Oramed Pharmaceuticals Inc. a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced it has completed enrollment of all patients in a Phase 2 trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis. An estimated 1.5% to 6.5% of adults in the U.S., or between 4 million and 17 million people, have NASH and about half of these also have diabetes, according to the National Institute of Diabetes and Dige...

Read More
news image

Business Insights

OPTIMIZERX ACQUIRES EVINCEMED, A SPECIALTY DRUG PRESCRIPTION INITIATION PLATFORM

OptimizeRx Corporation | March 16, 2022

OptimizeRx Corp. a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced a definitive agreement to acquire the EvinceMed platform and related assets. EvinceMed is a leader in delivering end-to-end automation for specialty pharmaceutical transactions. The acquisition includes the full Market Access Management Platform supporting pharma manufacturers, hub providers and pharmacies to improve patient access, speed to therapy and activation of af...

Read More
news image

PHARMACY MARKET, PHARMA TECH

TETRA BIO-PHARMA ANNOUNCES RESULTS OF ARTIFICIAL INTELLIGENCE STUDY OF ARDS-003 COMBINED WITH FAVIPIRAVIR

Tetra Bio-Pharma Inc. | December 07, 2022

Tetra Bio-Pharma Inc. a leader in cannabinoid-derived drug discovery and development announced significant results from the study of Onternabez combined with Favipiravir against ARDS powered platform which purposely integrates target identification, validation, lead discovery optimization, drug synthesis, and preclinical testing. Leveraging the power of AI enables more answers and greater insights, faster. Results from the study demonstrate that Tetra's investigational therape...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us